Arexvy is a brand-name respiratory syncytial virus (RSV) vaccine. It’s used in some adults to help prevent lung disease from RSV. Arexvy should not be used during pregnancy and breastfeeding ...

Shingrix is approved to prevent shingles (herpes zoster) in adults aged 50 and older. Arexvy is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory ...

The best logo maker helps you craft the right branding for your business - even if you've never designed a logo before. Our team of expert reviewers have tested the best free logo makers and the ...

GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co ...

The company studied co-administration of its RSV vaccine Arexvy and Shingrix in a phase 3 study of 530 adults age 50 years and older. When the shots were given during the same doctor's visit ...

Findings showed a noninferior immune response for both vaccines when coadministered compared with separate administration. Topline results were announced from a phase 3 study assessing the immune ...

AREXVY is approved for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older, as well as individuals 50 ...

Historically, the British drugmaker’s R&D returns were dominated by its HIV treatments and Shingrix and Arexvy vaccines, they say. Shares are down 0.9%. ([email protected]) ...

GSK plc GSK announced positive topline results from a phase III study evaluating the co-administration of its two marketed vaccines — RSV vaccine Arexvy and shingles vaccine Shingrix — in ...

(RTTNews) - GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY when co ...